Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in active Lupus Nephritis
NCT04883619Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nipocalimab in lupus nephritis (LN), sponsored by Janssen Pharmaceutical. Planned start Jan 2026; status: withdrawn.
02
Drugs
nipocalimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04883619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883619.